J, d. l. R., R, A., ME, C., E, A., A, G., C, A., . . . A, A. (2023). Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain.
Citación estilo ChicagoJ, de la Rubia, et al. Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain. 2023.
Cita MLAJ, de la Rubia, et al. Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain. 2023.
Precaución: Estas citas no son 100% exactas.